Last reviewed · How we verify
NCT06592625
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
Phase 2 trial testing SHR-A1811 in Untreated Early-stage or Locally Advanced Breast Cancer in 60 participants. Not yet recruiting.
28 February 2026
Quick facts
| Lead sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 20 September 2024 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR-A1811 — full drug profile →
- Adebrelimab — full drug profile →
Conditions studied
- Untreated Early-stage or Locally Advanced Breast Cancer — all drugs for Untreated Early-stage or Locally Advanced Breast Cancer →
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, female only, with Untreated Early-stage or Locally Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally advanced HR-negative or low expression, HER2 low expression breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06592625
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SHR-A1811
Trials testing the same drug.
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07466927 — Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver · Phase 2 · not yet recruiting
- NCT07382687 — Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer Wit · Phase 3 · not yet recruiting
- NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting
Other Suzhou Suncadia Biopharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT06844474 — A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC · Phase 2 · recruiting
- NCT06703177 — A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT06643754 — A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT06618651 — A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors · Phase 1 · recruiting
- NCT06640257 — A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06592625 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592625.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing